Asset Details
Do you wish to reserve the book?
Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report
Do you wish to request the book?
Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report
2026
Overview
Oral decitabine/cedazuridine has been studied in chronic myelomonocytic leukemia (CMML) recently but the molecular changes during this treatment have not been reported so far. We report a CMML patient who was treated with oral decitabine/cedazuridine and showed a stepwise loss of KRAS mutation and trisomy 8 while the TET2 mutated clone gradually increased eventually resulting in clonal hematopoiesis. This case report highlights the disease modifying potential of this treatment in single CMML patients.
